Selecting CD Treatment in Special Scenarios
Experts in gastroenterology discuss treatment selection in special situations of CD, such as age, women considering pregnancy, and extra-intestinal manifestations.
Use of Upadacitinib in Treatment of CD
Remo Panaccione, MD, FRCPC, provides an overview of the newest oral therapy approved for CD, upadacitinib.
Sequence Study of Risankizumab vs Ustekinumab in CD
David Rubin, MD, leads the panel discussion on a head-to-head sequence study of rizankizumab vs ustekinumab in the treatment of CD, as well as approaches to choosing first-line treatment.
Role of IL-12/23 Inhibitors and IL-23 Inhibitors in CD
David Rubin, MD, reviews the use of IL-12 and IL-23 inhibitors in the treatment of CD, highlighting ustekinumab and risankizumab for first-line therapy and beyond.
Anti-TNF and Anti-Integrins for Treatment of CD
Experts in gastroenterology provide an overview of anti-TNF (tumor necrosis factor) and anti-integrin therapies in treatment of CD.
Encouraging Patients for Biologic Use in Early Treatment of CD
Sara Horst, MD, MPH, and Miguel Regueiro, MD, comment on the changing treatment landscape of CD, as well as share approaches to communicate with patients about starting biologic treatment early on in CD.
Engaging Patients to Achieve Treatment Goals in CD
Experts in gastroenterology share approaches to engaging patients in achieving treatment targets beyond symptom control.
Monitoring Treatment Response in Treat-to-Target in CD
Experts continue the discussion on treat-to-target in CD, highlighting monitoring treatment response.
Treat-to-Target in CD
Miguel Regueiro, MD, and David Rubin, MD, review the treat-to-target strategy in relation to CD management, and how treat-to-target moves beyond symptom control.
Starting Biologic Treatment Early in CD
Sara Horst, MD, MPH, comments on early introduction of biologics in the treatment of CD, highlighting her approach to initiating conversations with patients about advanced therapy.
Moving Beyond Symptom Control in CD
Experts discuss the idea that, while symptoms of Crohn’s disease (CD) contribute to a patient’s quality of life, symptom control alone is not sufficient and the focus should be modifying the disease process.
Factors Guiding Treatment Choice in Crohn’s Disease
Dr Sara Horst leads the discussion on the commonly followed treatment approach in the community for moderate to severe Crohn's Disease (CD) and highlights the factors that should guide treatment choices.
2 Commerce Drive Cranbury, NJ 08512